Research

Mixed

GLP-1 receptor agonists and dual GIP/GLP-1 agonists cause unintended nutritional complications, including severe caloric restriction (<800 kcal/day), lean body mass loss (approx. 25-45% of total weight loss), micronutrient deficiencies, dehydration, and rare ketoacidosis, necessitating structured dietitian-led monitoring.

If you are taking GLP-1 medications like semaglutide or tirzepatide, do not rely on appetite alone to guide your diet. You are at risk of losing muscle and missing essential nutrients. Aim for at least 1200-1500 kcal/day and 1-1.4 grams of protein per kilogram of body weight daily. Prioritize nutrient-dense foods and stay hydrated. Work with a dietitian to monitor your intake and adjust your plan to prevent fatigue, dizziness, or muscle loss.

ModerateQualifiesMEDIUM confidence
Obesity pharmacotherapy vastly improved the treatment of the disease of obesity. However, GLP-1 receptor agonists and GIP/GLP-1 dual agonists may lead to nutritional complications, including severe caloric restriction, micronutrient deficiencies, lean body mass loss, dehydration, and ketosis.
Werd Al‐Najim et al. · Nutrients · 2025

Why this rating

Based on a narrative review synthesizing clinical trials, observational studies, and case reports; not a single high-quality RCT.

Source

Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes

Werd Al‐Najim et al. · Nutrients · 2025

DOI 10.3390/nu17111934

narrative_reviewCited 10×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →